Rivaroxaban 2.5 mg
CR014710
Phase 3 small_molecule completed
Quick answer
Rivaroxaban 2.5 mg for Acute Coronary Syndrome is a Phase 3 program (small_molecule) at Johnson & Johnson Pharmaceutical Research & Development, L.L.C. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Indication
- Acute Coronary Syndrome
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed